About Rgenta
Rgenta is a company based in Cambridge (United States) founded in 2018 by Zhiping Weng, Simon Xi, and Travis Wager. Rgenta has raised $90 million across 5 funding rounds from investors including Astrazeneca, HHS and Delos Capital. The company has 11 employees as of December 31, 2021. Rgenta offers products and services including RNA-Targeting Medicines and Discovery Platform. Rgenta operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Cambridge, United States
- Employees 11 as on 31 Dec, 2021
- Founders Zhiping Weng, Simon Xi, Travis Wager
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rgenta Therapeutics, Inc.,
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$90 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Astrazeneca
& 11 more
-
Employee Count
11
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rgenta
Rgenta offers a comprehensive portfolio of products and services, including RNA-Targeting Medicines and Discovery Platform.
Oral small-molecule drugs for treating oncology and neurological disorders.
Platform for developing RNA-targeted small molecule therapies.
Funding Insights of Rgenta
Rgenta has successfully raised a total of $90M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rgenta
Rgenta has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, HHS and Delos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Delos Capital is engaged in private equity and financial advisory services.
|
Locked | Locked | Locked | |
|
Early-stage ventures are funded by the investment firm.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked |
Investor details for Rgenta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rgenta
Investment portfolio details for Rgenta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rgenta
Detailed financials for Rgenta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rgenta Comparisons
Peer comparison for Rgenta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rgenta
Rgenta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Rgenta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rgenta
Complete news archive for Rgenta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rgenta
Rgenta was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Rgenta is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Simon Xi is the current CEO of Rgenta. They have also founded this company.
Rgenta is a funded company, having raised a total of $90M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Rgenta is 11.
Founded in 2018 and based in Cambridge, United States, Rgenta operates in the biotechnology sector. RNA-based therapeutics are developed to address various disorders through compound libraries designed to identify and modulate RNA target sites, especially those involving regulatory proteins. A data-driven platform for mRNA target identification is utilized, incorporating cell type-specific regulation to forecast outcomes of target modulation.
Rgenta's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Rgenta offers RNA-Targeting Medicines and Discovery Platform.
Rgenta has 12 investors. Key investors include Astrazeneca, HHS, Delos Capital, Matrix, and Lilly Asia Ventures.